Epoprostenol (FLOLAN) is an intravenous medication used to treat primary pulmonary hypertension (PPH), a condition characterized by progressive increases in pulmonary artery pressure, leading to ...

Study objectives: Prior to the availability of the oral endothelin antagonist bosentan, most patients with pulmonary arterial hypertension (PAH) were treated with continuously infused ...

Prostacyclin analogs are a standard long-term treatment for severe PAH. Flolan (epoprostenol) was the first drug in this class. It is used in severe cases if other treatments aren’t working well ...

They were given long term intravenous prostaglandin treatment (either epoprostenol (n = 61) or iloprost (n = 13)) or conventional treatment with oral anticoagulants (n = 24) with or without calcium ...

15,16 “In patients with PAH initiating therapy with IV epoprostenol, we suggest against the routine simultaneous initiation of bosentan.” (Ungraded consensus-based statement 7) “For WHO FC III or IV ...

Prostacyclin analogs are a standard long-term treatment for severe PAH. Flolan (epoprostenol) was the first drug in this class. It is used in severe cases if other treatments aren’t working well ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

The mechanism of thrombocytopenia during acute pulmonary hypertension (PH) decompensation may be partly due to platelet aggregation in the lung. Platelet aggregates in explanted lung from 16 lung ...